Mike Blum

Mike Blum has a strong background in commercial operations and strategy in the biotechnology and pharmaceutical industry. Mike is currently serving as the Chief Commercial Officer (CCO) at Homology Medicines, Inc. since March 2022. Prior to this, they held the role of Senior Vice President (SVP) of Commercial at the same company starting in January 2020. Mike has been with Homology Medicines, Inc. since 2017, initially joining as the Vice President (VP) of Commercial Strategy.

Before joining Homology Medicines, Inc., Mike Blum worked at Zafgen, Inc. from 2015 to 2017, where they served as the Head of Commercial Operations. Prior to this, they worked at Sarepta Therapeutics from 2013 to 2015, leading the market access function and focusing on rare disease patient access to medications in various markets.

From 2009 to 2013, Mike Blum held the position of Vice President (VP) of US Commercial Operations at Shire HGT, where they were responsible for leading all commercial operations and decision-making in North America. Prior to this, they served as Senior Director of US Sales & Reimbursement and Director of US Reimbursement and Distribution at Shire HGT from 2005 to 2009.

Mike Blum started their career at Biogen Idec in 2004, serving as Assistant Director of Business Relations Managers.

Mike Blum's education history begins in 1985 when they enrolled at the College of the Holy Cross. Mike completed their studies in 1989 and earned a Bachelor of Arts (B.A.) degree in English Language and Literature, focusing on a general curriculum.

After a gap of several years, Mike pursued further education in 1997 by joining the Babson F.W. Olin Graduate School of Business. Mike completed their studies there in 2001 and obtained a Master of Business Administration (MBA) degree. The field of study during their MBA program is unspecified.

In summary, Mike Blum holds a Bachelor of Arts (B.A.) degree in English Language and Literature from the College of the Holy Cross, earned in 1989, and a Master of Business Administration (MBA) degree from the Babson F.W. Olin Graduate School of Business, obtained in 2001.